What's the reality of today's increase in AS to 250 million

New Post Public Reply Private Reply Replies (3) Message Board
Bsav88atty
Today I've received numerous emails, texts, PMs, and phone calls asking my thoughts and opinions on today's 14C filing in which the company notified its shareholders that the amount of authorized shares increased over 65% from 150 million to 250 million. To be blunt, I was disappointed with today's news. I fully expect the PPS to take a hit tomorrow as CHP and the gang work their magic, though I hope I'm wrong. Not everything ScripsAmerica does will be positive, and we will not always agree with the decisions the company makes from time to time. That said, I'm not selling my 2 million shares, as I sincerely believe much better news is just around the corner.

As Bob pointed out during my rant with him this evening (he's probably not too happy with me for such rant), this is merely an increase in the authorized shares, not the outstanding shares. Bob also said the company "has not made any plans to issue other shares." So in reality, what we have is an increase in the number of shares the company is "authorized" to make. To error on the side of caution, however, I will increase the number of outstanding shares in all my future longterm price projections from my prior 150 million assumptions to 200 million shares, which is about 75 million more shares than the company reported two weeks ago. For am example of how this will impact my most recent projections, below is my stickied post with the new 200 million OS assumptions in italics and bold. (Note to management, this is NOT to be read as a Bsav88atty endorsement for issuing an additional 75 million shares.) As you will see, my PPS projections drop a little, but not by a significant amount...

ScripsAmerica still has at least seven potential revenue streams (excluding the DOD revs). At least three of these revenue streams will be generating revenues in May -- Main Ave Pharmacy, WholesaleRx, and RapiMeds Hong Kong. Below are my projected May revenues and NET PROFIT for each (yes, I'm predicting the company will turn a profit and prove all the iHub bashers wrong once and for all):

1. Main Ave Pharmacy - $750,000 ($353,400 to SCRC per disclosure the 10K -- $750K Xs 97% Xs 20% estimated sales commission based on industry norms Xs 30% for all Main Ave expenses identified in the agreement that Flyers posted on iHub (thanks, Flyers for posting details, very helpful!) - minus $54K monthly payment to Mr. Fox based on $30 Xs 250 scripts in April -- I do not know how much to include for the "Finance Fee" that is to be paid to SCRC per the agreement, so I will ignore it to be conservative. I understand that it in the compounding pharmacy industry, the profit margins are "extremely favorable" per the core's research and the company's Q&A. So the 70% profit margin that I have assumed here is reasonably attainable.)

2. WholesaleRx - $400,000 ($56,000 - 70% gross margin, 20% of gross margin to SCRC -- This is based on prior filings and appears to be pure profit.)

3. PIMD - $0 (unfortunately, it is earning $0 per the 10K; this was my biggest disappointment from the 10K, hopefully, the company can get moving with this in June as stated in the 10K.)

4. RapiMed Hong Kong -$200,000 ($200,000 to SCRC, assumes no more orders in May; I will assume 30% profit margin, so $60,000 to the bottom line. This is another revenue stream that has been much slower to develop than initially anticipated. Perhaps it will ignite in 2H FY14.)

5. RapiMed Mainland China - $0 (product approval possibly as early as June, same comments as Hong Kong)

6. RapiMed Canada - $0 (no updates, probably nothing until the second half of 2014)

7. RapiMed US - $0 (not my favorite potential stream of revenue)

An eighth potential revenue stream is the Global Pharma Hub, but I'll ignore that one as well.

So in May, excluding the DOD revenues and the "financing fees" from Main Ave, I am projecting revenues of $609,000 to SCRC and $469,400 of gross profit. I'll further assume $200,000 for SG&A, which translates to about $269,400 in NET PROFIT. Assuming no further increases, my net profit/earnings estimate would equate to $3,232,800 through April 30, 2015. I will further assume the total shares outstanding increases to 150,000,000, so eps of $0.02, and a PE of 20 (which is uber conservative for such explosive growth). If I am correct, May's earnings would support a pps of at least $0.40. I do not, however, expect the status quo. I expect much more growth.

New assumption: I will further assume the total shares outstanding increases to 200,000,000, so eps of $0.016, and a PE of 20 (which is uber conservative for such explosive growth). If I am correct, May's earnings would support a pps of at least $0.32. I do not, however, expect the status quo. I expect much more growth.

Indeed, I believe May will be the tip of the iceberg as Scrips continues to grow and fill in all seven of its potential revenue streams (again, excluding the DOD revenues, Main Ave "financing fee", and Global Pharma Hub). For example, if Scrips was able to grow only the Main Ave Pharmacy monthly revenues to $2,000,000 based on 700 scripts (as the Atlanta compounding pharmacy monthly revenues that Guts discovered last week), SCRC's monthly revenues would be $1,342,400, its gross profit about $1,202,400, and net profit of about $1M -- or $12M in net profit over 12 months. (This is pre-tax, and I'll have to find the NOL carry forward to determine a more accurate net earnings.) Applying the same numbers as above (e.g., 150M OS, 20 PE), would yield an eps of $0.08 and a corresponding stock price of $1.60.

New Assumption: Applying the same numbers as above (e.g., 200M OS, 20 PE), would yield an eps of $0.06 and a corresponding stock price of $1.20.

Incidentally, if the company was to issue 75 million shares tomorrow at a dime, that would equate to over $7 million to the company after commissions, underwriter fees, and other fees and expenses. I understand a portion of these shares will be used to compensate management and be reserved for the preferred share conversions, but I believe it is safe to assume the company would have at $4 million to which it could use for accretive acquisitions, further accelerating the company's amazing growth. Indeed, it is not difficult for me to imagine a scenario where Team Scrips could put together a few more acquisitions to double, triple or even quadruple my projected revenues and, thus, an even higher stock price than I estimated above. So, while things do appear a bit grim now, in my humble opinion, we are very close to breaking out. Indeed, despite the ugly 2013 10K and today's increase in the AS, I sincerely believe 2014 will be an exciting year to be a Scrips shareholder. Hang in there everyone, we will soon have ignition and liftoff (albeit a bit more selling pressure before liftoff)!

Good luck!

Bsav88atty

P.S. I did not get paid to write this message, nor have I been paid to post any message at any time on any board.

ScripsAmerica Inc (SCRC) Stock Research Links

SCRC Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 93

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading
Refund Delays Are Becoming an E-Commerce Sales Risk

Updated Category News Views 176

A returned jacket can turn into a household cash-flow problem faster than retailers seem willing to admit. Seel's new survey lands at an awkward moment for online merchants: shoppers are not merely annoyed by slow refunds; many are budgeting around them. Among 1,921 U.S. adults who had shopped online in the prior six months, 63% said waiting for a retailer to receive a...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 130

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 51

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 45

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
CATL Builds Türkiye Battery Service Muscle in Istanbul

Updated Category News Views 43

Battery warranties look mighty impressive until a pack needs work on a Tuesday morning and nobody nearby can touch it. CATL's new NING SERVICE Experience Center in Istanbul goes straight at that unglamorous problem. The facility, announced November 19, 2026, is described as Türkiye's first dedicated battery depot repair center and an integrated sales-and-service hub. It...

Continue Reading
Compounded Peptides Demand Clearer FDA Status Answers

Updated Category News Views 73

Peptide talk has gotten muddled enough to make plain English feel revolutionary. The central point in the HelloNation article featuring wellness expert Andres Giraldo is straightforward: a compounded peptide is not FDA approved in the same product-specific manner as a commercially manufactured drug. That is not a small semantic wrinkle, and it should not be buried beneath...

Continue Reading
Lowe's Dec. 9 Conference Puts Strategy on the Clock

Updated Category News Views 148

A Calendar Entry With Real Weight December 9 is not earnings day, but it is the sort of date shareholders ought to circle anyway. Lowe's plans to hold its 2026 Analyst and Investor Conference at 8 a.m. Eastern time in New York City, with a live webcast available for those not sitting in the room. For owners of NYSE:LOW, these gatherings can be more useful than the usual...

Continue Reading
IT Tech Packaging's Going-Concern Warning Lands Hard

Updated Category News Views 76

A paper maker can survive plenty of ugly quarters; it cannot casually shrug off an auditor questioning whether it can keep operating. That is the cold part of IT Tech Packaging's Nov. 19 disclosure. Its newly filed Form 10-K for the year ended Dec. 31, 2025 carries a “Material Uncertainty Related to Going Concern” paragraph from Audit Alliance LLP. Nobody should dress...

Continue Reading
AIM Academy Accreditation Signals a Broader Quality Push

Updated Category News Views 50

Early-childhood education does not hand out many clean, easily comparable scorecards, which is precisely why AIM Academy’s new Cognia recognition deserves a closer look. The Alabama provider has earned Cognia Initial Accreditation, while its Pike Road center received Accreditation with Merit after its Initial Accreditation Review. That is not a revenue event, not a...

Continue Reading

Top 5 Most Recently Viewed Articles

Alfa Laval Enhances Gulf Coast Support with La Porte Expansion

Updated Category News Views 183

Alfa Laval Strengthens Local Support with La Porte Service Center Alfa Laval, a world leader in heat transfer, separation, and fluid handling, is proud to announce the expansion of its Service Center in La Porte, Texas. This newly expanded facility is set to bolster the support for the Gulf Coast's industrial community, demonstrating the company’s commitment to local...

Continue Reading
AgEagle Aerial Systems Achieves Impressive Q1 Financial Gains

Updated Category News Views 209

AgEagle Aerial Systems Achieves Strong Financial Results A remarkable transformation is underway at AgEagle Aerial Systems Inc. (NYSE: UAVS), a key player in unmanned aerial systems (UAS) and sensor technology. The company has announced financial results for the first quarter of fiscal year 2025, showcasing a sharp recovery and robust performance in various financial...

Continue Reading
Empowering Future Leaders: The 6th Student Research Competition

Updated Category News Views 259

Empowering Future Leaders: The 6th Student Research Competition The Fixed Income Analysts Society (FIASI), in partnership with Fordham University's Center for Research in Contemporary Finance and the O'Shea Center for Credit Analysis and Investment, is excited to announce the launch of its highly anticipated 6th Annual FIASI – Gabelli School Student Research...

Continue Reading
LALO Tequila Unveils Unique 2025 High Proof Blanco Expression

Updated Category News Views 414

Introducing the 2025 High Proof Blanco Tequila LALO Tequila proudly presents its latest creation, the 2025 High Proof Blanco, marking a significant chapter in its celebrated line of limited-edition spirits. Scheduled just in time for Hispanic Heritage Month, this release embodies the brand’s strong cultural roots while embracing modern advancements in the tequila...

Continue Reading
TaskUs, Inc. to Reveal Q3 2024 Earnings on November 7

Updated Category News Views 95

TaskUs, Inc. to Reveal Financial Results for Q3 2024 TaskUs, Inc. (Nasdaq: TASK), a prominent leader in providing outsourced digital services and advanced customer experience, will disclose its third quarter 2024 financial results following the market's closure on November 7. Conference Call and Webcast Details Management will conduct a conference call and webcast at 5:00...

Continue Reading